QNRX VS HOTH Stock Comparison
Performance
QNRX10/100
10/100
QNRX returned -81.93% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
HOTH10/100
10/100
HOTH returned -72.17% in the last 12 months. Based on SPY's performance of 11.08%, its performance is below average giving it a score of 10 of 100.
Technicals
QNRX29/100
29/100
QNRX receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.
HOTH11/100
11/100
HOTH receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
QNRX10/100
10/100
QNRX has missed earnings 5 times in the last 20 quarters.
HOTH10/100
10/100
HOTH has missed earnings 12 times in the last 20 quarters.
Profit
QNRX10/100
10/100
Out of the last 14 quarters, QNRX has had 0 profitable quarters and has increased their profits year over year on 0 of them.
HOTH10/100
10/100
Out of the last 20 quarters, HOTH has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
QNRX35/100
35/100
QNRX has had a lower than average amount of volatility over the last 12 months giving it a score of 35 of 100.
HOTH57/100
57/100
HOTH has had a higher than average amount of volatility over the last 12 months giving it a score of 57 of 100.
Sentiment
QNRX
"Sentiment" not found for QNRX
HOTH68/100
68/100
HOTH had a bullish sentiment score of 68.41% across Twitter and StockTwits over the last 12 months. It had an average of 1.50 posts, 0.10 comments, and 0.30 likes per day.
All score calculations are broken down here to help you make more informed investing decisions
Quoin Pharmaceuticals, Ltd. American Depositary Shares Summary
Nasdaq / QNRX
Healthcare
Biotechnology
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Hoth Therapeutics, Inc. Common Stock Summary
Nasdaq / HOTH
Healthcare
Biotechnology
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare QNRX to other companies in the same or a similar industry.